LT2935320T - Stabilizuoti insulino tipo augimo faktoriaus polipeptidai - Google Patents

Stabilizuoti insulino tipo augimo faktoriaus polipeptidai

Info

Publication number
LT2935320T
LT2935320T LT13828987T LT13828987T LT2935320T LT 2935320 T LT2935320 T LT 2935320T LT 13828987 T LT13828987 T LT 13828987T LT 13828987 T LT13828987 T LT 13828987T LT 2935320 T LT2935320 T LT 2935320T
Authority
LT
Lithuania
Prior art keywords
growth factor
type growth
factor polypeptides
insulin type
stabilized insulin
Prior art date
Application number
LT13828987T
Other languages
English (en)
Inventor
Mara Fornaro
Thomas Huber
Mauro Zurini
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2935320(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT2935320T publication Critical patent/LT2935320T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/65Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LT13828987T 2012-12-18 2013-12-16 Stabilizuoti insulino tipo augimo faktoriaus polipeptidai LT2935320T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261738475P 2012-12-18 2012-12-18
PCT/IB2013/060985 WO2014097116A1 (en) 2012-12-18 2013-12-16 Stabilized insulin-like growth factor polypeptides

Publications (1)

Publication Number Publication Date
LT2935320T true LT2935320T (lt) 2019-11-11

Family

ID=50073229

Family Applications (1)

Application Number Title Priority Date Filing Date
LT13828987T LT2935320T (lt) 2012-12-18 2013-12-16 Stabilizuoti insulino tipo augimo faktoriaus polipeptidai

Country Status (36)

Country Link
US (1) US10167329B2 (lt)
EP (2) EP2935320B1 (lt)
JP (1) JP6499080B2 (lt)
KR (1) KR102182523B1 (lt)
CN (1) CN105121462B (lt)
AP (1) AP2015008440A0 (lt)
AU (1) AU2013365796B2 (lt)
BR (1) BR112015013708B1 (lt)
CA (1) CA2894976C (lt)
CL (1) CL2015001708A1 (lt)
CR (2) CR20200079A (lt)
CU (1) CU24308B1 (lt)
CY (1) CY1122309T1 (lt)
DK (1) DK2935320T3 (lt)
EA (1) EA034356B1 (lt)
EC (1) ECSP15031046A (lt)
ES (1) ES2756330T3 (lt)
GT (1) GT201500168A (lt)
HR (1) HRP20191965T1 (lt)
HU (1) HUE047386T2 (lt)
IL (1) IL239387A0 (lt)
LT (1) LT2935320T (lt)
MA (1) MA38153B1 (lt)
MX (1) MX363021B (lt)
MY (1) MY174820A (lt)
NZ (1) NZ708091A (lt)
PE (2) PE20200894A1 (lt)
PH (1) PH12015501271A1 (lt)
PL (1) PL2935320T3 (lt)
PT (1) PT2935320T (lt)
RS (1) RS59545B1 (lt)
SA (1) SA515360603B1 (lt)
SG (1) SG11201503782PA (lt)
SI (1) SI2935320T1 (lt)
TN (1) TN2015000182A1 (lt)
WO (1) WO2014097116A1 (lt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160091888A (ko) * 2013-10-02 2016-08-03 노파르티스 아게 요법에 사용하기 위한 인슐린-유사 성장 인자 모방체
CN109153708A (zh) * 2016-03-04 2019-01-04 夏尔人类遗传性治疗公司 重组卵泡抑素-fc融合蛋白及其在治疗杜氏肌营养不良症中的应用
US10953074B2 (en) * 2017-01-08 2021-03-23 Richard D. Lippman Composition and method for improving sensorineural hearing
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
EP3813861A4 (en) * 2018-06-27 2022-08-10 Juvena Therapeutics, Inc. HEPARIN-ASSOCIATED POLYPEPTIDES AND THEIR USES
CN109053875B (zh) * 2018-08-31 2021-06-29 重庆大学 突变型igf-1、重组质粒、重组蛋白及应用
RU2711111C1 (ru) * 2018-09-05 2020-01-15 Илья Владимирович Духовлинов Гибридный белок igf-1-long для лечения инсульта, нуклеиновая кислота, вектор, клетка, фармацевтическая композиция, способ лечения
CN110642937B (zh) * 2019-10-11 2021-04-06 南开大学 多肽衍生物、纳米纤维及其应用
CN115379850A (zh) 2019-12-24 2022-11-22 裘美娜治疗公司 再生性多肽及其用途
CN117999278A (zh) 2021-06-21 2024-05-07 裘美娜治疗公司 再生性多肽及其用途
WO2025106529A2 (en) * 2023-11-14 2025-05-22 Cavalry Biosciences, Inc. Compositions for targeting muscle cells and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DE60042550D1 (de) * 1999-01-06 2009-08-27 Genentech Inc Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
DK2322631T3 (en) 2001-04-19 2015-01-12 Scripps Research Inst Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar
WO2005033134A2 (en) 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Secreted protein therapeutics and uses thereof
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
ATE517120T1 (de) * 2005-01-07 2011-08-15 Regeneron Pharma Igf-1 fusion polypeptide und deren therapeutische verwendung
US7521211B2 (en) * 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
CL2007001614A1 (es) 2006-06-09 2008-08-08 Novartis Ag Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t
CN101466398A (zh) * 2006-06-09 2009-06-24 诺瓦提斯公司 稳定的胰岛素样生长因子多肽
EP2227546B1 (en) 2007-12-21 2016-05-04 Novartis AG Mammalian expression vector
EA027071B1 (ru) 2009-04-27 2017-06-30 Новартис Аг АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ
WO2011011071A2 (en) 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
WO2011011073A1 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1
WO2014097113A2 (en) 2012-12-18 2014-06-26 Novartis Ag Production of therapeutic proteins in genetically modified mammalian cells
KR20160091888A (ko) 2013-10-02 2016-08-03 노파르티스 아게 요법에 사용하기 위한 인슐린-유사 성장 인자 모방체
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas

Also Published As

Publication number Publication date
CR20200079A (es) 2020-03-21
ES2756330T3 (es) 2020-04-27
CU20150064A7 (es) 2016-02-29
TN2015000182A1 (en) 2016-10-03
BR112015013708B1 (pt) 2022-10-18
CU24308B1 (es) 2018-01-10
ECSP15031046A (es) 2019-03-29
EP2935320B1 (en) 2019-08-21
PE20151612A1 (es) 2015-11-19
HK1212712A1 (en) 2016-06-17
CL2015001708A1 (es) 2015-08-28
WO2014097116A1 (en) 2014-06-26
EP2935320A1 (en) 2015-10-28
AP2015008440A0 (en) 2015-05-31
MY174820A (en) 2020-05-17
AU2013365796A1 (en) 2015-05-28
BR112015013708A2 (pt) 2017-11-14
PL2935320T3 (pl) 2020-03-31
PE20200894A1 (es) 2020-09-08
CN105121462B (zh) 2019-08-02
EP3626735A1 (en) 2020-03-25
CR20150324A (es) 2015-08-10
PH12015501271B1 (en) 2015-08-24
MX2015007932A (es) 2015-10-05
US10167329B2 (en) 2019-01-01
SI2935320T1 (sl) 2019-12-31
NZ708091A (en) 2018-03-23
PH12015501271A1 (en) 2015-08-24
MX363021B (es) 2019-03-05
GT201500168A (es) 2016-01-21
JP6499080B2 (ja) 2019-04-10
JP2016501025A (ja) 2016-01-18
IL239387A0 (en) 2015-07-30
SA515360603B1 (ar) 2020-07-26
PT2935320T (pt) 2019-11-15
CN105121462A (zh) 2015-12-02
RS59545B1 (sr) 2019-12-31
CA2894976C (en) 2022-10-04
DK2935320T3 (da) 2019-11-18
HUE047386T2 (hu) 2020-04-28
EA034356B1 (ru) 2020-01-30
AU2013365796B2 (en) 2017-03-30
KR20150095879A (ko) 2015-08-21
SG11201503782PA (en) 2015-06-29
US20150329614A1 (en) 2015-11-19
CA2894976A1 (en) 2014-06-26
EA201591165A1 (ru) 2015-11-30
HRP20191965T1 (hr) 2020-01-24
CY1122309T1 (el) 2021-01-27
MA38153A1 (fr) 2016-06-30
KR102182523B1 (ko) 2020-11-25
MA38153B1 (fr) 2018-06-29

Similar Documents

Publication Publication Date Title
IL261632B (en) Chimeric factor viii polypeptides and uses thereof
LT2935320T (lt) Stabilizuoti insulino tipo augimo faktoriaus polipeptidai
EP2839019A4 (en) CD3 BINDING POLYPEPTIDES
DK2705144T4 (da) Polypeptid
EP2940135A4 (en) HETERODIMIZED POLYPEPTIDE
DK3536310T3 (da) Sprøjte
DK3685826T3 (da) Sprøjte
LT3473714T (lt) Polipeptidai, pasižymintys transgalaktozilinimo aktyvumu
EP2832391A4 (en) SYRINGE
PL2863942T3 (pl) Cząstki sprzężone z peptydem
FI20116212L (fi) Polypeptidi
HRP20181662T1 (hr) Poboljšani čvrsti herbicidni pripravci s integralnim adjuvansom
EP2913076A4 (en) SYRINGE
EP2956160A4 (en) INSULIN SECRETATING POLYPEPTIDES
CU24181B1 (es) POLIPÉPTIDOS DERIVADOS DEL TGFß
PL2746059T3 (pl) Element zabezpieczający z efektem nachylenia
DK2718316T3 (da) Polypeptider
CL2013001996S1 (es) Envase tipo contenedor
FI20120373L (fi) Opiskelu- ja työtuoli
FR2987422B1 (fr) Plateforme stabilisee
EP2885023A4 (en) SYRINGE